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Available online 30 July 2014AbstractHyponatremia is an uncommon adverse effect of antipsychotic drug use. Syndrome of inappropriate secretion of antidiuretic hormone
(SIADH) is one of the common causes of hyponatremia. We report a case of hyponatremic seizure due to SIADH caused by the antipsychotic
drug risperidone, which resolved on stopping the drug. This case highlights the need for clinicians to be aware of the rare, potentially life-
threatening but preventable hyponatremia as an adverse effect of risperidone.
Copyright © 2014, Taiwan Society of Emergency Medicine. Published by Elsevier Taiwan LLC. All rights reserved.
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Serotonergic drugs such as selective serotonin reuptake
inhibitors and serotoninenorepinephrine reuptake inhibitors
are known to cause syndrome of inappropriate secretion of
antidiuretic hormone (SIADH). Antipsychotics are the main-
stay of treatment for patients with schizophrenia. One of the
uncommon side effects of psychotropic drugs is the develop-
ment of hyponatremia, which is considered to be caused by the
release of an antidiuretic hormone (ADH).1 However, the as-
sociation of SIADH with antipsychotics is not well under-
stood. We present the case of a patient who developed SIADH
after being started on risperidone.
2. Case Report
A 22-year-old female presented to the psychiatry outpatient
department with a history of 1 year of illness characterized by* Corresponding author. Department of Medicine, University College of
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2211-5587/Copyright © 2014, Taiwan Society of Emergency Medicine. Publishedpersecutory beliefs, referential ideas, hallucinatory behavior, and
disturbed sleep and appetite. The patientwas treatment naïve and
had visited only faith healerswithout any contactwithmedical or
psychiatric services. There was no history suggestive of poly-
dipsia. The mental status examination result was consistent with
the diagnosis of paranoid schizophrenia. Her physical exami-
nation did not reveal any sign of physical illness, and routine
blood tests did not reveal any abnormality. She was started on
risperidone tablet (2 mg/day), which she tolerated well. The
dosage of risperidonewas increased to 4mg/day after 3 days. She
was not prescribed any other medications. After 5 days of initi-
ation of risperidone, she had an episode of generalized ton-
iceclonic seizures, for which she was hospitalized, and detailed
medicalworkupwas done.At the time of hospitalization, shewas
drowsy and her vital signs and physical examination results were
normal.On laboratory investigations, her blood sugarwas 90mg/
dL. The results of serum-related investigations revealed the
following: sodium, 118 mEq/dL; potassium, 4.1 mEq/dL; uric
acid, 2.0 mg/dL; calcium, 8.4 mg/dL; osmolarity, and
258mOsm/kg ofwater. Her blood urea nitrogenwas 10mEq/dL,
her urinary sodiumwas 34mEq/L, and the result of urine routine
and microscopic examination was normal. The serum cortisol
and thyroid profilewas normal. Imaging scans including chestX-by Elsevier Taiwan LLC. All rights reserved.
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Cerebrospinal fluid analysis yielded normal results.
The patient was diagnosed to have SIADH, and risperidone
(tablet) was stopped. She was treated with water restriction
and infusion of 3% hypertonic saline at a rate 0.05 mL/kg
body weight per minute with monitoring of serum sodium and
urinary output. Her serum sodium increased to 126 mEq/dL on
the 2nd day and 134 mEq/dL on the 3rd day. At that time, she
did not have any physical complaints and mental status
returned to normal.
3. Discussion
Hyponatremia is a common electrolyte disturbance and has
been defined as serum sodium levels of <135 mEq/L and
considered severe when the serum level is <125 mEq/L.2
Clinically, hyponatremia may be “silent” or may present
with malaise, muscle ache, nausea, vomiting, or with severe
manifestations such as seizures, delirium, coma, and even
death.3 The syndrome of inappropriate ADH secretion is the
cause of hyponatremia in around one-third of all cases.4
Various psychotropic agents including selective serotonin re-
uptake inhibitors, tricyclic antidepressants, monoamine oxi-
dase inhibitors, and antiepileptic drugs have been known to
cause hyponatremia, mostly by inducing SIADH.5
Antipsychotic drugs, both typical and atypical, have also
been reported to cause SIADH.1 The mechanism by which
antipsychotics cause SIADH is not yet clear. Various hy-
potheses have been suggested, including long-term D2 re-
ceptor blockade leading to D2 receptor super sensitivity,
which in turn results in ADH release,6,7 antipsychotic-induced
hypotension leading to ADH release through baroreceptor
reflex, and serotonin-mediated effects on central 5-
hydroxytryptamine (5-HT)2 and 5-HT1c receptors stimu-
lating ADH secretion.8,9
As our patient did not show any symptom(s) of hypotension
and her blood pressure was normal, and also given the fact that
she was on risperidone for only 5 days (making the possibility
of D2 supersensitivity unlikely), we hypothesize that the
SIADH was mediated by the action of risperidone on 5-HT
receptors.
Risperidone can cause hyponatremia and seizure. However,
it is a rare side effect of this drug. During the double-blind
placebo-controlled trials for oral risperidone, <1% of adults
and <5% of pediatric patients reported experiencing thirst,d
and risperidone was suspected of causing polydipsia.10 This
mechanism may be relevant to the development of hypona-
tremia. During premarketing trials, seizure occurred in 0.3%
of patients who received oral risperidone (9 of 2607)ef and ind Product information: RISPERDAL MeTAB oral disintegrating tablets,
risperidone oral disintegrating tablets. Janssen (per FDA), Titusville, NJ; 2011.
e Product Information: RISPERDAL,RISPERDAL oral tablets, solution,
risperidone oral tablets, solution, orally disintegrating tablets. Janssen, Divi-
sion of Ortho-McNeil-Janssen Pharmaceuticals, Inc., Titusville, NJ; 2010.
f Product Information: RISPERDAL MeTAB orally disintegrating tablets,
risperidone orally disintegrating tablets. Janssen Ortho, LLC, Titusville, NJ;
2010.3% of patients who received long-acting intramuscular ris-
peridone (5 of 1499).g Two cases of seizures reported with oral
therapy were associated with hyponatremia. Risperidone
should be used cautiously in patients with a history of seizure.
In this case, clinical history and investigations were
consistent with the diagnosis of SIADH. The lack of history of
polydipsia and onset of hyponatremia with seizures shortly
after starting of risperidone and rapid correction of serum
sodium after stopping it makes a relationship with the drug
likely. The case adds to the existing data of antipsychotic
induced SIADH and also proposes a plausible mechanism for
the same.
4. Conclusion
This case report highlights the possibility of the life-
threatening adverse effect of SIADH due to antipsychotic
drug use in a patient of psychosis. We recommend that mea-
surement of serum sodium levels as a baseline and after
initiation of antipsychotics be made a routine clinical practice.
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